Not a good buy right now for an impatient trader: price is sitting just above key support (~27.60) with bearish momentum (MACD expanding negative) and weak short-term pattern odds (-3.03% 1W, -5.95% 1M).
Options sentiment is bullish (very low put/call), but that is not being confirmed by the chart yet; risk is a support break toward ~25.64.
Near-term upside is catalyst-driven (Q1 2026 AATD/BEAM-302 updates), so this is better treated as an event trade after technical stabilization rather than buying immediately into weakness.
Intellectia Proprietary Trading Signals: No signal on given stock today.
Trend/Momentum: Bearish near-term. MACD histogram -0.662 and negatively expanding signals downside momentum is strengthening.
RSI: RSI_6 = 32.825 (near-oversold area), suggesting selling pressure is elevated, but not yet a clean reversal signal.
Moving averages: Converging MAs suggests consolidation, but currently not confirming an uptrend.
Key levels: Price (27.9) is below pivot 30.791 and just above S1 27.605; a clean break below S1 increases odds of a move toward S2 25.637. Bulls need a reclaim of the pivot (30.8) to improve trend quality.
Pattern-based forward odds (given): 40% chance of +1.01% next day, but negative bias over 1W and 1M.
Activity: Options volume elevated (today vs 30D avg volume 117.65%), and open interest elevated vs average (138.97%), showing active positioning.
Volatility/price of options: IV percentile 2 and IV rank 5.06 implies implied vol is very low relative to its own history (options relatively “cheap”), despite high historical volatility (79). This often precedes larger moves but does not dictate direction.
Net read: Options market leans bullish, but it’s not yet aligned with the bearish technical momentum—watch for price confirmation before treating it as a clean long signal.
Technical Summary
Sell
7
Buy
5
Positive Catalysts
Regulatory update already viewed positively for the Alpha-1 Antitrypsin Deficiency (AATD) program; multiple analysts cite 2026 as catalyst-heavy.
Upcoming: Updated AATD/BEAM-302 data expected in Q1 2026 is a key event-driven upside catalyst.
Positioning: Hedge funds are buying (reported buying amount +161.22% QoQ), supportive for sentiment/flows.
Street stance: Multiple Outperform/Buy ratings with targets well above current price (e.g., $35, $41, $45).
Neutral/Negative Catalysts
Company fundamentals remain loss-making; biotech catalysts can dominate price action, increasing binary event risk.
Financial Performance
Latest provided quarter: 2025/Q3.
Revenue: 9.70M, down -32.03% YoY (top-line contraction).
Profitability: Net income -112.73M (still a large loss) but improved ~16.61% YoY (loss narrowed).
EPS: -1.10, down -5.98% YoY (slightly worse per-share).
Gross margin: 100% (likely reflects revenue mix; does not offset the large operating loss).
Overall: Financials show ongoing heavy cash burn/loss profile; the stock is primarily catalyst- and pipeline-driven rather than fundamentals-driven right now.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Ratings/targets have generally moved up into 2026 on AATD optimism.
Bernstein (2026-01-20): Outperform; PT raised to $41 from $37 on positive regulatory update; highlights more events through year end and Q1 2026 data.
BofA (2026-01-06): Buy; PT raised to $45 from $43; constructive on biotech backdrop.
UBS (2026-01-07): Initiated Neutral; PT $28 (closest to current price), implying more balanced risk/reward near term.
Wall Street pros/cons view: Pros = strong upcoming catalysts and platform potential; Cons = execution/catalyst dependence, ongoing losses, and near-term technical weakness.
Wall Street analysts forecast BEAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAM is 42 USD with a low forecast of 21 USD and a high forecast of 80 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast BEAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAM is 42 USD with a low forecast of 21 USD and a high forecast of 80 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
3 Hold
0 Sell
Strong Buy
Current: 24.730
Low
21
Averages
42
High
80
Current: 24.730
Low
21
Averages
42
High
80
Bernstein
Outperform
maintain
$37 -> $41
AI Analysis
2026-01-20
Reason
Bernstein
Price Target
$37 -> $41
AI Analysis
2026-01-20
maintain
Outperform
Reason
Bernstein raised the firm's price target on Beam Therapeutics to $41 from $37 and keeps an Outperform rating on the shares. The firm raised its price target following last week's positive regulatory update on the Alpha-1 Antitrypsin Deficiency program. While Last week's regulatory event was the main 2026 stock catalyst the firm was playing for, there are still several important events to track through the year end, including updated AATD data in Q126, the analyst tells investors in a research note.
UBS
Michael Yee
Neutral
initiated
$28
2026-01-07
Reason
UBS
Michael Yee
Price Target
$28
2026-01-07
initiated
Neutral
Reason
UBS analyst Michael Yee initiated coverage of Beam Therapeutics (BEAM) with a Neutral rating and $28 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BEAM
